ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

IFM to tackle innate immunity

by Lisa M. Jarvis
June 27, 2016 | APPEARED IN VOLUME 94, ISSUE 26

IFM Therapeutics, a biotech firm developing small molecules that modulate the innate immune system, has debuted with $27 million in funding from Atlas Venture, Abingworth, and Novartis. The innate immune system represents the first line of defense against an infection. IFM hopes to treat cancer by enhancing that defense and tackle inflammatory diseases by dampening it. The cash will be used to advance IFM’s early-stage drug portfolio and start clinical studies of its lead compound, a cancer treatment. IFM was founded by Gary Glick, an academic chemist turned entrepreneur who previously started Lycera.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment